Author Index to Volume 56

Abelson JL. *See* Cameron OG; Young EA
Ackenheil M. *See* Zill P
Adrover M. *See* Argyropoulos SV
Agam G. *See* Shaltiel G
Akiyama T. *See* Washizuka S
Allen G, Müller R-A, Courchesne E. Cerebellar function in autism: functional magnetic resonance image activation during a simple motor task, 269
Allen JS. *See* Buchanan TW
Alm B. *See* Kellner M
Altemus M, Fong J, Yang R, Damast S, Luine V, Ferguson D. Changes in cerebrospinal fluid neurochemistry during pregnancyh, 386
Altshuler LL, Ventura J, van Gorp WG, Green MF, Theberge DC, Mintz J. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects, 560
Anand A. *See* Kugaya A
Andersen SL. *See* Teicher MH
Anderson ER. *See* Vythilingam M
Anderson GM. *See* Carpenter LL; Vythilingam M
Anderson V. *See* Wang X
Anllo-Vento L. *See* Feifel D
Apud JA. *See* Weickert TW
Archer SL. *See* Chrapko WE
Argyropoulos SV, Hood SD, Adrover M, Bell CJ, Rich AS, Nash JR, Rich NC, Witchel HJ, Nutt DJ. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder, 503
Arinami T. *See* Iijima Y
Arnold LM. *See* Hudson JI
Arranz M-J. *See* Parsons MJ
Asada T. *See* Ide M
Asghar SJ. *See* Willson MC
Asherson PJ. *See* D'Souza UM
Ashkenazi M. *See* Korostishevsky M
Auchenbach MB. *See* Hudson JI
Avramopoulos D. *See* Stefanis NC
Axelson D. *See* Chen BK
Azevedo M-H. *See* Wong AHC

Baba K. *See* Yamada K
Badner JA. *See* Schulze TG
Bagary MS, Hutton SB, Symms MR, Barker GJ, Mutsatsa SH, Barnes TRE, Joyce EM, Ron MA. Structural neural networks subserving oculomotor function in first-episode schizophrenia, 620
Bagby RM. *See* Praschak-Rieder N
Bai J, He F, Novikova SI, Undie AS, Dracheva S, Haroutunian V, Lidow MS. Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins, 427
Baird AA. *See* Gordon HL
Baldwin RM. *See* Fujita M; Kugaya A
Bar G. *See* Kremer I
Barch DM. *See* Green MF
Barker GJ. *See* Bagary MS
Barnes TRE. *See* Bagary MS; Hutton SB
Bartenstein P. *See* Fellgiebel A
Bartko JJ. *See* Sunderland T
Baschirotto C. *See* Nobile M
Basile VS. *See* Levitan RD
Battaglia M. *See* Nobile M
Bayerlein K. *See* Bönsch D
Beauvais JE. *See* Tucker KA
Becker A. *See* Keilhoff G
Beech RD. *See* Caldarone BJ
Behrens TEJ. *See* Ramnani N
Bekris L. *See* Padmos RC
Bell CJ. *See* Argyropoulos SV
Bell EC. *See* Willson MC
Bell JM. *See* Ghelardoni S
Bellina M. *See* Nobile M
Bellodi L. *See* Caldirola D
Bellomo A. *See* Bertolino A
Belmaker RH. *See* Shaltiel G
Ben-Asher E. *See* Korostishevsky M
Bening-Abu-Shach U. *See* Korostishevsky M
Bergeson J. *See* Sunderland T
Bernstein H-G. *See* Keilhoff G
Bernstein J. *See* Korostishevsky M
Berrettini WH. *See* Schulze TG
Bertolino A, Blasi G, Caforio G, Latorre V, De Candia M, Rubino V, Callicott JH, Mattay VS, Bellomo A, Scarabino T, Weinberger DR, Nardini M. Functional lateralization of the sensorimotor cortex in patients with schizophrenia: effects of treatment with olanzapine, 190
Bhupali D. *See* Sunderland T
Bialer M. *See* Shaltiel G
Biggs MM. *See* Rush AJ
Birmaher B. *See* Chen BK
Bissette G. *See* Hibbeln JR
Bjarkam CR, Sørensen JC. Therapeutic strategies for neurodegenerative disorders: emerging clues from Parkinson's disease, 213
Blanaru M. *See* Kremer I
Blasi G. *See* Bertolino A
Bleich S. *See* Bönsch D
Blennow K. *See* Schmitt A
Bondy B. *See* Zill P
Bönsch D, Reulbach U, Bayerlein K, Hillemacher T, Kornhuber J, Bleich S. Elevated alpha synuclein mRNA levels are associated with craving in patients with alcoholism, 984
Booij J. *See* Lindauer RJL
Bosetti F. *See* Ghelardoni S
Bozkurt A. *See* Fujita M; Kugaya A
Brambilla P. *See* Chen BK; Sassi RB
Brammer MJ. *See* Jones HM
Braus DF. *See* Schmitt A
Bremner JD. *See* Vythilingam M
Breslau N. *See* Young EA
Brown RG. *See* Jones HM
Brown RW, Flanigan TJ, Thompson KN, Thacker SK, Schaefer TL, Williams MT. Neonatal quinpirole treatment impairs Morris water task performance in early postweaning rats: relationship to increases in corticosterone and decreases in neutrophic factors, 161
Brown TL. *See* Oxley T
Browndyke JN. *See* Tucker KA
Browner WS. *See* Otte C
Buchanan TW, Kern S, Allen JS, Tranel D, Kirschbaum C. Circadian regulation of cortisol after hippocampal damage in humans, 651
Buervenich S. *See* Schulze TG

0006-3223/04/$30.00
doi:10.1016/S0006-3223(04)01195-3

BIOL PSYCHIATRY 2004;56:994–1003

© 2004 Society of Biological Psychiatry

Burnham WM. *See* Murphy P
Büttner A. *See* Zill P
Byerley W. *See* Schulze TG

Caforio G. *See* Bertolino A
Cain MS. *See* Manoach DS
Calabrese JR, Vieta E, El-Mallakh R, Findling RL, Youngstrom EA, Elhaj O, Gajwani P, Pies R. Mood state at entry as predictor of the polarity of relapse in bipolar disorder, 957
Caldarone BJ, Harrist A, Cleary MA, Beech RD, King SL, Picciotto MR. High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation, 657
Caldirola D, Bellodi L, Cammino S, Perna G. Smoking and respiratory irregularity in panic disorder, 393
Callicott JH. *See* Bertolino A
Cameron OG. *See* Young EA
Cameron OG, Abelson JL, Young EA. Anxious and depressive disorders and their comorbidity: effect on central nervous system noradrenergic function, 875
Cammino S. *See* Caldirola D
Cannistraro PA, Wright CI, Wedig MM, Martis B, Shin LM, Wilhelm S, Rauch SL. Amygdala responses to human faces in obsessive-compulsive disorder, 916
Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-a, 819
Carella A. *See* Praschak-Rieder N
Carlier IVE. *See* Lindauer RJL
Carmody TJ. *See* Rush AJ
Carpenter LL. *See* Tyrka AR
Carpenter LL, Moreno FA, Kling MA, Anderson GM, Regenold WT, Labiner DM, Price LH. Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients, 418
Carpenter WT. *See* Frost DO
Carroll KM. Behavioral therapies for co-occurring substance use and mood disorders, 778
Cataldo MG. *See* Nobile M
Cauich C. *See* Müller R-A
Caviness V. *See* Frost DO
Celda-Navarro N. *See* Pico-Alfonso MA
Chambers RA, Taylor JR. Animal modeling dual diagnosis schizophrenia: sensitization to cocaine in rats with neonatal ventral hippocampal lesions, 308
Chapple B. *See* Toulopoulou T
Charney D. *See* Kugaya A
Charney DS. *See* Monk CS; Vythilingam M; Zarate CA Jr
Chen BK, Sassi R, Axelson D, Hatch JP, Sanches M, Nicoletti M, Brambilla P, Keshavan MS, Ryan ND, Birmaher B, Soares JC. Cross-sectional study of abnormal amygdala development in adolescents and young adults with bipolar disorder, 399
Chen Q, He G, Wang XY, Chen QY, Liu XM, Gu ZZ, Liu J, Li KQ, Wang SJ, Zhu SM, Feng GY, He L. Positive association between *synapsin II* and schizophrenia, 177
Chen QY. *See* Chen Q
Cholostoy A. *See* Korostishevsky M
Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Mellédo J-M. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder, 129
Cleary MA. *See* Caldarone BJ
Clementz BA. *See* Feifel D
Cohen D. *See* Padmos RC
Cohen J. *See* Green MF
Cohen RM. *See* Sunderland T
Comtois KA, Russo JE, Roy-Byrne P, Ries RK. Clinicians' assessments of bipolar disorder and substance abuse as predictors of suicidal behavior in acutely hospitalized psychiatric inpatients, 757
Coplan JD. *See* Gorman JM
Corcoran C. *See* Malaspina D
Coryell W. *See* Schulze TG
Courchesne E. *See* Allen G; Müller R-A
Cox NJ. *See* Schulze TG
Coyne JC. *See* Palmer SC
Craig IW. *See* D'Souza UM
Crandall JE. *See* Luo T
Crawford TJ. *See* Hutton SB
Crismon ML. *See* Rush AJ
Crusio WE. Flanking gene and genetic background problems in genetically manipulated mice, 381
Csako G. *See* Sunderland T

Dager SR. *See* Friedman SD
Dahary D. *See* Korostishevsky M
Dalton E. *See* Shaltiel G
Damast S. *See* Altemus M
Daskalakis ZJ. *See* Oxley T
Daumann J, Fischermann T, Heekeren K, Thron A, Gouzoulis-Mayfrank E. Neural mechanisms of working memory in ectasy (MDMA) users who continue or discontinue ectasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study, 349
Davis C. *See* Levitan RD
Davis N. *See* van Haren NEM
De Candia M. *See* Bertolino A
de Castella A. *See* Oxley T
de la Fuente-Fernández R, Schulzer M, Stoessl AJ. Placebo mechanisms and reward circuitry: clues from Parkinson's disease, 67
de Leeuw F-E. *See* Janssen J
DeMartino R. *See* Power K
Demopulos C. *See* Friedman SD
den Heeten GJ. *See* Lindauer RJL
Denicoff KD. *See* Zarate CA Jr
Denucci CC. *See* Fujita M
DePaulo R Jr. *See* Schulze TG
Detera-Wadleigh SD. *See* Schulze TG
Dettling AC. *See* Pryce CR
Dhavale D. *See* Torrey EF
Dick D. *See* Schulze TG
Dickson JM. *See* Wignall EL
Dillon MS. *See* Fujita M
Ding D. *See* Shaltiel G
Dow-Edwards D. *See* Wang X
Dracheva S. *See* Bai J
Dräger UC. *See* Luo T
Drake RE, Xie H, McHugo GJ, Shumway M. Three-year outcomes of long-term patients with co-occurring bipolar and substance use disorders, 749
Drexhage HA. *See* Padmos RC
D'Souza UM. *See* Parsons MJ
D'Souza UM, Russ C, Tahir E, Mill J, McGuffin P, Asherson PJ,

Craig IW. Functional effects of a tandem duplication polymorphism in the 5' flanking region of the DRD4 gene, 691
Dudai Y. *See* Guitton MJ
Duman RS. *See* Kodama M; Wallace TL
Duman RS. Depression: a case of neuronal life and death?, 140
Dumont NL. *See* Teicher MH
Dunn E. *See* Praschak-Rieder N
Dunner DL. *See* Friedman SD
Durham R. *See* Sunderland T
Dwivedi Y, Mondal AC, Shukla PK, Rizavi HS, Lyons J. Altered protein kinase A in brain of learned helpless rats: effects of acute and repeated stress, 30

Egan MF. *See* Weickert TW
Eisenmenger W. *See* Zill P
Elhaj O. *See* Calabrese JR
Ellison-Wright I. *See* McDonald C
El-Mallakh R. *See* Calabrese JR
Ely TD. *See* Schweitzer JB
Emanuelsson C. *See* Erhardt S
End A. *See* Gordon HL
Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition, 255
Ernst D. *See* Lang N
Ernst M. *See* Monk CS
Essock S. *See* Green MF
Ethier I, Kagechika H, Shudo K, Rouillard C, Lévesque D. Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of *Nur77* and retinoid receptors, 522
Evdokimidis I. *See* Stefanis NC

Farber GA, Goldberg JF. Regarding "combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind randomized study": optimizing initial interventions, 535
Farber RH. *See* Feifel D
Farrow TFD. *See* Wignall EL
Fegert JM. *See* Vitiello B
Feifel D, Farber RH, Clementz BA, Perry W, Anllo-Vento L. Inhibitory deficits in ocular motor behavior in adults with attention-deficit/hyperactivity disorder, 333
Feldon J. *See* Pryce CR
Fellgiebel A, Siessmeier T, Scheurich A, Winterer G, Bartenstein P, Schmidt LG, Müller MJ. Association of elevated phospho-tau levels with Alzheimer-typical ^{18}F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment, 279
Feng GY. *See* Chen Q
Fenton WS. *See* Green MF
Ferguson D. *See* Altemus M
Findling RL. *See* Calabrese JR
Fischermann T. *See* Daumann J
Fitzgerald PB. *See* Oxley T
Flanigan TJ. *See* Brown RW
Fong J. *See* Altemus M
Foroud T. *See* Schulze TG
Forrester K. *See* McIntosh AM
Frank E. *See* Sassi RB
Frese F. *See* Green MF
Fricks L. Why are we here? A patient's perspective on living with an untreated dual diagnosis, 726
Friedman D. *See* Sunderland T
Friedman L. *See* Stockmeier CA
Friedman SD, Dager SR, Parow A, Hirashima F, Demopulos C, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder, 340
Frost DO, Tamminga CA, Medoff DR, Caviness V, Innocenti G, Carpenter WT. Neuroplasticity and schizophrenia, 540
Fujioka T. *See* Kodama M
Fujita M, Southwick SM, Denucci CC, Zoghbi SS, Dillon MS, Baldwin RM, Bozkurt A, Kugaya A, Verhoeff NPLG, Seibyl JP, Innis RB. Central type benzodiazepine receptors in Gulf War veterans with posttraumatic stress disorder, 95
Fukunaga T. *See* Kunugi H

Gajwani P. *See* Calabrese JR
Garcia-Linares MI. *See* Pico-Alfonso MA
Gattaz WF. *See* Schmitt A
Gelernter J. *See* Stein MB
George DT. *See* Hibbeln JR
Gershon ES. *See* Schulze TG
Gersons BPR. *See* Lindauer RJL
Gessa GL. *See* Pistis M
Geyer MA. *See* Erhardt S; Harte MK
Ghelardoni S, Tomita YA, Bell JM, Rapoport SI, Bosetti F. Chronic carbamazepine selectively downregulates cytosolic phospholipase A_2 expression and cyclooxygenase activity in rat brain, 248
Giedd JN. *See* Teicher MH
Giorda R. *See* Nobile M
Glauer M. *See* Straube T
Gobbini MI. *See* Leibenluft E
Goff DC. *See* Manoach DS
Gold JM. *See* Green MF
Goldberg JF. *See* Farber GA
Goldberg TE. *See* Green MF; Weickert TW
Gonzales JJ, Insel TR. The conundrum of co-occurring mental and substance use disorders: opportunities for research, 723
Gordon HL, Baird AA, End A. Functional differences among those high and low on a trait measure of psychopathy, 516
Gorelik I. *See* Kremer I
Gorman JM. *See* Malaspina D
Gorman JM, Martinez J, Coplan JD, Kent J, Kleber M. The effect of successful treatment on the emotional and physiological response to carbon dioxide inhalation in patients with panic disorder, 862
Gottheil E. *See* Mannelli P
Gottschalk C. *See* Tucker KA
Gouzoulis-Mayfrank E. *See* Daumann J
Grafton ST. *See* Schweitzer JB
Grant BF. *See* Li T-K
Grech A. *See* Toulopoulou T
Grecksch G. *See* Keilhoff G
Green MF. *See* Altshuler LL
Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RSE, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria, 301
Greenberg ML. *See* Shaltiel G
Greenhill LL. *See* Vitiello B

Grillon C, Smith K, Haynos A, Nieman LK. Deficits in hippocampus-mediated Pavlovian conditioning in endogenous hypercortisolism, 837
Gu ZZ. *See* Chen Q
Guitton MJ, Dudai Y. Anxiety-like state associates with taste to produce conditioned taste aversion, 901
Guyer AE. *See* Monk CS

Habraken JBA. *See* Lindauer RJL
Hamazaki K. *See* Huan M
Hamazaki T. *See* Huan M
Hanford RB. *See* Schweitzer JB
Hantoumi I. *See* Stefanis NC
Hanusa BH. *See* Wisner KL
Harkavy-Friedman J. *See* Malaspina D
Haroutunian V. *See* Bai J
Harris JM, Whalley H, Yates S, Miller P, Johnstone EC, Lawrie SM. Abnormal cortical folding in high-risk individuals: a predictor of the development of schizophrenia?, 182
Harrison LK. *See* McIntosh AM
Harrison T. *See* Leibenluft E
Harrist A. *See* Caldarone BJ
Harte MK, Powell SB, Reynolds LM, Swerdlow NR, Geyer MA, Reynolds GP. Reduced *N*-acetylaspartate in the temporal cortex of rats reared in isolation, 296
Harwood AJ. *See* Shaltiel G
Hashimoto R. *See* Kunugi H
Hatch JP. *See* Chen BK; Sassi RB
Hattori E. *See* Yamada K
Haxby JV. *See* Leibenluft E
Haynos A. *See* Grillon C
He F. *See* Bai J
He G. *See* Chen Q
He L. *See* Chen Q
Heaton RK. *See* Green MF
Heekeren K. *See* Daumann J
Heeren TJ. *See* Janssen J
Heiligenstein JH. *See* Vitiello B
Henn FA, Vollmayr B. Neurogenesis and depression: etiology or epiphenomenon?, 146
Hennessy G. *See* Levin FR
Herbert J. *See* Pico-Alfonso MA
Heresco-Levy U. *See* Kremer I
Hewitt BG. *See* Li T-K
Hibbeln JR, Bissette G, Umhau JC, George DT. Omega-3 status and cerebrospinal fluid corticotrophin releasing hormone in perpetrators of domestic violence, 895
Hillemacher T. *See* Bönsch D
Hirashima F. *See* Friedman SD
Hoffman JM. *See* Schweitzer JB
Honda A. *See* Yamada K
Honer WG. *See* Wong AHC
Hood SD. *See* Argyropoulos SV
Hossain A. *See* Tucker P
Houle S. *See* Praschak-Rieder N
Huan M, Hamazaki K, Sun Y, Itomura M, Liu H, Kang W, Watanabe S, Terasawa K, Hamazaki T. Suicide attempt and n-3 fatty acid levels in red blood cells: a case control study in China, 490
Huddy V. *See* Hutton SB
Hudson JI, Arnold LM, Keck PE Jr, Auchenbach MB, Pope HG Jr. Family study of fibromyalgia and affective spectrum disorder, 884
Hunter MD. *See* Wignall EL
Hurd YL. *See* Wang X
Hussey D. *See* Praschak-Rieder N
Hutton SB. *See* Bagary MS
Hutton SB, Huddy V, Barnes TRE, Robbins TW, Crawford TJ, Kennard C, Joyce EM. The relationship between antisaccades, smooth pursuit, and executive dysfunction in first-episode schizophrenia, 553

Ibrahim H. *See* Rush AJ
Ide M, Muratake T, Yamada K, Iwayama-Shigeno Y, Iwamoto K, Takao H, Toyota T, Kaneko N, Minabe Y, Nakamura K, Kato T, Mori N, Asada T, Someya T, Yoshikawa T. Genetic and expression analyses of *FZD3* in schizophrenia, 462
Iijima Y. *See* Kunugi H
Iijima Y, Inada T, Ohtsuki T, Senoo H, Nakatani M, Arinami T. Association between chromogranin B gene polymorphisms and schizophrenia in the Japanese population, 10
Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y, Inada T, Ozaki N. Association of AKT1 with schizophrenia confirmed in a Japanese population, 698
Inada T. *See* Iijima Y; Ikeda M; Kunugi H
Innis RB. *See* Fujita M; Kugaya A
Innocenti G. *See* Frost DO
Insel TR. *See* Gonzales JJ
Ito Y. *See* Teicher MH
Itomura M. *See* Huan M
Iwamoto K. *See* Ide M; Washizuka S
Iwata N. *See* Ikeda M; Kunugi H
Iwata Y. *See* Yamada K
Iwayama-Shigeno Y. *See* Ide M; Yamada K

Jalink M. *See* Lindauer RJL
Janssen J, Pol HEH, Lampe IK, Schnack HG, de Leeuw F-E, Kahn RS, Heeren TJ. Hippocampal changes and white matter lesions in early-onset depression, 825
Jatzko A. *See* Schmitt A
Javitt DC. *See* Kremer I
Job DE. *See* McIntosh AM
Johnston EC. *See* McIntosh AM
Johnstone EC. *See* Harris JM
Jones HM, Brammer MJ, O'Toole M, Taylor T, Ohlsen RI, Brown RG, Purvis R, Williams SS, Pilowsky LS. Cortical effects of quetiapine in first-episode schizophrenia: a preliminary functional magnetic resonance imaging study, 938
Joyce EM. *See* Bagary MS; Hutton SB
Jurasz P. *See* Chrapko WE
Jurjus GJ. *See* Stockmeier CA

Kaganovich M. *See* Korostishevsky M
Kagechika H. *See* Ethier I
Kahn RS. *See* Janssen J; van Haren NEM
Kakiuchi C. *See* Washizuka S
Kalidindi S. *See* McDonald C
Kametani M. *See* Washizuka S
Kaneko N. *See* Ide M
Kang W. *See* Huan M
Kaplan AS. *See* Levitan RD
Katayama T. *See* Yamada K
Kato T. *See* Ide M; Kunugi H; Washizuka S
Kazuno A-a. *See* Washizuka S
Keck PE Jr. *See* Hudson JI

Keefe RSE. *See* Green MF
Keilhoff G, Bernstein H-G, Becker A, Grecksch G, Wolf G. Increased neurogenesis in a rat ketamine model of schizophrenia, 317
Kellner M, Schick M, Yassouridis A, Struttmann T, Wiedemann K, Alm B. Metyrapone tests in patients with panic disorder, 898
Kelsoe JR. *See* Schulze TG
Kennard C. *See* Hutton SB
Kennedy JL. *See* Levitan RD; Wong AHC
Kennedy N. *See* McDonald C
Kennedy SH. *See* Levitan RD
Kent J. *See* Gorman JM
Kern RS. *See* Green MF
Kern S. *See* Buchanan TW
Kerwin RW. *See* Parsons MJ
Keshavan MS. *See* Chen BK; Sassi RB
Kessler KC. The epidemiology of dual diagnosis, 730
Khan S. *See* Kugaya A
Khurana A. *See* Manoach DS
Kilts CD. *See* Rilling JK; Schweitzer JB
Kimmel L. *See* Sunderland T
King SL. *See* Caldarone BJ
Kinoshita Y. *See* Ikeda M
Kirschbaum C. *See* Buchanan TW
Kirwin PD. *See* Tyrka AR
Kitajima T. *See* Ikeda M
Kleber M. *See* Gorman JM
Kleinman JE. *See* Perlman WR
Klempan T. *See* Wong AHC
Kling MA. *See* Carpenter LL
Knijff EM. *See* Padmos RC
Kodama M, Fujioka T, Duman RS. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat, 570
Kolachana BS. *See* Weickert TW
Kolassa I-T. *See* Straube T
Konick LC. *See* Stockmeier CA
Kornhuber J. *See* Bönsch D
Korostishevsky M, Kaganovich M, Cholostoy A, Ashkenazi M, Ratner Y, Dahary D, Bernstein J, Bening-Abu-Shach U, Ben-Asher E, Lancet D, Ritsner M, Navon R. Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis, 169
Kosten TA. *See* Kosten TR
Kosten TR. *See* Tucker KA
Kosten TR, Kosten TA. New medication strategies for comorbid substance use and bipolar affective disorders, 771
Kraemer H. *See* Green MF
Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt DC, Heresco-Levy U. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia, 441
Kugaya A. *See* Fujita M
Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, Anand A, van Dyck CH, Baldwin RM, Seibyl JP, Charney D, Innis RB. Brain serotonin transporter availabilty predicts treatment response to selective serotonin reuptake inhibitors, 497
Kulkarni J. *See* Oxley T
Kunugi H. *See* Washizuka S
Kunugi H, Iijima Y, Tatsumi M, Yoshida M, Hashimoto R, Kato T, Sakamoto K, Fukunaga T, Inada T, Suzuki T, Iwata N, Ozaki N, Yamada K, Yoshikawa T. No association between the Val66Met polymorphism of the brain-derived neurotrophic factor gene and bipolar disorder in a Japanese population: a multicenter study, 376
Kupfer DJ. *See* Sassi RB
Kupka RW. *See* Padmos RC

Labiner DM. *See* Carpenter LL
Lam RW. *See* Levitan RD
Lampe IK. *See* Janssen J
Lancet D. *See* Korostishevsky M
Lang N, Siebner HR, Ernst D, Nitsche MA, Paulus W, Lemon RN, Rothwell JC. Preconditioning with transcranial direct current stimulation sensitizes the motor cortex to rapid-rate transcranial magnetic stimulation and controls the direction of after-effects, 634
Lara N. *See* Chrapko WE
Latorre V. *See* Bertolino A
Lawlor JP. *See* Torrey EF
Lawrie SM. *See* Harris JM; McIntosh AM
Le Mellédo J-M. *See* Chrapko WE
Lee DO. *See* Schweitzer JB
Lee M. *See* Praschak-Rieder N
Leibenluft E. *See* Monk CS
Leibenluft E, Gobbini MI, Harrison T, Haxby JV. Mothers' neural activation in response to pictures of their children and other children, 225
Lemon RN. *See* Lang N
Lernmark A. *See* Padmos RC
Leuner B, Mendolia-Loffredo S, Shors TJ. Males and females respond differently to controllability and antidepressant treatment, 964
Lévesque D. *See* Ethier I
Levin FR. *See* Nunes EV
Levin FR, Hennessy G. Bipolar disorder and substance abuse, 738
Levitan RD, Masellis M, Basile VS, Lam RW, Kaplan AS, Davis C, Muglia P, Mackenzie B, Tharmalingam S, Kennedy SH, Macciardi F, Kennedy JL. The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: an evolutionary perspective, 665
Levitt P. *See* Pongrac JL
Levy JA. *See* Sunderland T
Lewis DA. *See* Pongrac JL
Lewis L. Dual diagnosis: The Depression and Bipolar Support Alliance's patient perspective, 728
Li KQ. *See* Chen Q
Li T-K, Hewitt BG, Grant BF. Alcohol use disorders and mood disorders: a National Institute on Alcohol Abuse and Alcoholism perspective, 718
Lidow MS. *See* Bai J
Likhodi O. *See* Wong AHC
Likhodii S. *See* Murphy P
Lindauer RJL, Booij J, Habraken JBA, Uylings HBM, Olff M, Carlier IVE, den Heeten GJ, van Eck-Smit BLF, Gersons BPR. Cerebral blood flow changes during script-driven imagery in police officers with posttraumatic stress disorder, 853
Lindauer RJL, Vlieger E-J, Jalink M, Olff M, Carlier IVE, Majoie CBLM, den Heeten GJ, Gersons BPR. Smallers hippocampal

volume in Dutch police officers with posttraumatic stress disorder, 356
Linker G. *See* Sunderland T
Liu H. *See* Huan M
Liu J. *See* Chen Q
Liu XM. *See* Chen Q
Luckenbaugh D. *See* Vythilingam M
Luckenbaugh DA. *See* Zarate CA Jr
Luine V. *See* Altemus M
Luo T, Wagner E, Crandall JE, Dräger UC. A retinoic-acid critical period in the early postnatal mouse brain, 971
Lyons J. *See* Dwivedi Y
Lyoo IK. *See* Friedman SD

Macciardi F. *See* Levitan RD
Macedo A. *See* Wong AHC
Mackenzie B. *See* Levitan RD
MacKinnon DF. *See* Schulze TG
Mahajan GJ. *See* Stockmeier CA
Majoie CBLM. *See* Lindauer RJL
Makoff AJ. *See* Parsons MJ
Malaspina D, Harkavy-Friedman J, Corcoran C, Mujica-Parodi L, Printz D, Gorman JM, Van Heertum R. Resting neural activity distinguishes subgroups of schizophrenia patients, 931
Malison RT. *See* Kugaya A
Mallinger AG. *See* Sassi RB
Manji HK. *See* Zarate CA Jr
Mannelli P, Gottheil E, Peoples JF, Oropeza VC, Van Bockstaele EJ. Chronic very low dose naltrexone administration attenuates opioid withdrawal expression, 261
Manoach DS, Cain MS, Vangel MG, Khurana A, Goff DC, Stickgold R. A failure of sleep-dependent procedural learning in chronic, medicated schizophrenia, 951
Maras A. *See* Schmitt A
Marder SR. *See* Green MF
Marino C. *See* Nobile M
Marmar CR. *See* Otte C
Marshall N. *See* van Haren NEM
Martinez J. *See* Gorman JM
Martinez M. *See* Pico-Alfonso MA
Martis B. *See* Cannistraro PA
Masellis M. *See* Levitan RD
Masters B. *See* Tucker P
Mattay VS. *See* Bertolino A
Matthews PM. *See* Ramnani N
McClure EB. *See* Monk CS
McDonald C. *See* Toulopoulou T; van Haren NEM
McDonald C, Zanelli J, Rabe-Hesketh S, Ellison-Wright I, Sham P, Kalidindi S, Murray RM, Kennedy N. Meta-analysis of magnetic resonance imaging brain morphometry studies in bipolar disorder, 411
McDougle CJ. *See* Tyrka AR
McGuffin P. *See* D'Souza UM
McHugo GJ. *See* Drake RE
McInnis MG. *See* Schulze TG
McIntosh AM, Job DE, Moorhead WJ, Harrison LK, Forrester K, Lawrie SM, Johnston EC. Voxel-based morphometry of patients with schizophrenia or bipolar disorder and their unaffected relatives, 544
McLellan AT, Meyers K. Contemporary addiction treatment: a review of systems problems for adults and adolescents, 764
McMahon FJ. *See* Schulze TG
Medoff DR. *See* Frost DO
Melis M. *See* Pistis M
Meltzer HY. *See* Stockmeier CA
Mendolia-Loffredo S. *See* Leuner B
Mentzel H-J. *See* Straube T
Meyer JH. *See* Praschak-Rieder N
Meyers K. *See* McLellan AT
Middleton FA. *See* Pongrac JL
Mill J. *See* D'Souza UM
Miller AH. *See* Capuron L
Miller P. *See* Harris JM
Miltner WHR. *See* Straube T
Minabe Y. *See* Ide M; Yamada K
Minkoff H. *See* Wang X
Mintz J. *See* Altshuler LL
Mirnics K. *See* Pongrac JL
Mirza N. *See* Sunderland T
Mishara A. *See* Weickert TW
Miyoshi K. *See* Yamada K
Mizuno A. *See* Müller R-A
Möller H-J. *See* Zill P
Molteni M. *See* Nobile M
Mondal AC. *See* Dwivedi Y
Monk CS, Nelson EE, Woldehawariat G, Montgomery LA, Zarahn E, McClure EB, Guyer AE, Leibenluft E, Charney DS, Ernst M, Pine DS. Experience-dependent plasticity for attention to threat: behavioral and neurophysiological evidence in humans, 607
Montgomery LA. *See* Monk CS
Moorhead WJ. *See* McIntosh AM
Moos R. *See* Otte C
Moreno FA. *See* Carpenter LL
Mori K. *See* Washizuka S
Mori N. *See* Ide M; Yamada K
Morris RG. *See* Toulopoulou T
Muglia P. *See* Levitan RD
Mujica-Parodi L. *See* Malaspina D
Müller MJ. *See* Fellgiebel A
Müller R-A. *See* Allen G
Müller R-A, Cauich C, Rubio MA, Mizuno A, Courchesne E. Abnormal activity pagtterns in premotor cortex during sequence learning in autistic patients, 323
Muntoni AL. *See* Pistis M
Muratake T. *See* Ide M
Murphy DL. *See* Schulze TG
Murphy P, Likhodii S, Nylen K, Burnham WM. The antidepressant properties of the ketogenic diet, 981
Murray RM. *See* McDonald C; Toulopoulou T; van Haren NEM
Mutsatsa SH. *See* Bagary MS

Nakamura K. *See* Ide M; Yamada K
Nakatani M. *See* Iijima Y
Nanko S. *See* Washizuka S
Nardini M. *See* Bertolino A
Nash JR. *See* Argyropoulos SV
Navon R. *See* Korostishevsky M
Nelson EE. *See* Monk CS
Nemeroff CB. *See* Tyrka AR
Neve RL. *See* Wallace TL
Nicoletti MA. *See* Chen BK; Sassi RB
Nieman LK. *See* Grillon C
Nitsche MA. *See* Lang N
Nobile M, Cataldo MG, Giorda R, Battaglia M, Baschirotto C,

Bellina M, Marino C, Molteni M. A case-control and family-based association study of the 5-HTTLPR in pediatric-onset depressive disorders, 292
Nolen DA. *See* Padmos RC
Novikova SI. *See* Bai J
Nuechterlein KH. *See* Green MF
Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence, 93
Nurnberger JI Jr. *See* Schulze TG
Nutt DJ. *See* Argyropoulos SV
Nylen K. *See* Murphy P

Ohlsen RI. *See* Jones HM
Ohtsuki T. *See* Iijima Y
Olff M. *See* Lindauer RJL
Oropeza VC. *See* Mannelli P
O'Toole M. *See* Jones HM
Otte C, Marmar CR, Pipkin SS, Moos R, Browner WS, Whooley MA. Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: the Heart and Soul Study, 241
Overholser JC. *See* Stockmeier CA
Owens MJ. *See* Tyrka AR
Oxley T, Fitzgerald PB, Brown TL, de Castella A, Daskalakis ZJ, Kulkarni J. Repetitive transcranial magnetic stimulation reveals abnormal plastic response to premotor cortex stimulation in schizophrenia, 628
Ozaki N. *See* Ikeda M; Kunugi H

Padmos RC, Bekris L, Knijff EM, Tiemeier H, Kupka RW, Cohen D, Nolen WA, Lernmark A, Drexhage HA. A high prevalence of organ-specific autoimmunity in patients with bipolar disorder, 476
Palmer SC, Coyne JC. Examining the evidence that psychotherapy improves the survival of cancer patients, 61
Parker DE. *See* Tucker P
Parow A. *See* Friedman SD
Parsons MJ, D'Souza UM, Arranz M-J, Kerwin RW, Makoff AJ. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity, 406
Parvin MM, Swartz C. Low efficacy electroconvulsive therapy in community settings, 905
Pato CN. *See* Wong AHC
Pato MT. *See* Wong AHC
Paulus W. *See* Lang N
Payne JL. *See* Zarate CA Jr
Peindl KS. *See* Wisner KL
Peng L. *See* Pongrac JL
Penny W. *See* Ramnani N
Peoples JF. *See* Mannelli P
Perel JM. *See* Wisner KL
Perlman WR, Webster MJ, Kleinman JE, Weickert CS. Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness, 844
Perna G. *See* Caldirola D
Perra S. *See* Pistis M
Perry W. *See* Feifel D
Petroianu G. *See* Schmitt A
Pettinati HM. Antidepressant treatment of co-occurring depression and alcohol dependence, 785
Picchioni MM. *See* van Haren NEM
Picciotto MR. *See* Caldarone BJ
Pico-Alfonso MA, Garcia-Linares MI, Celda-Navarro N, Herbert J, Martinez M. Changes in cortisol and dehydroepiandrosterone in women victims of physical and psychological intimate partner violence, 233
Pies R. *See* Calabrese JR
Pillolla G. *See* Pistis M
Pilowsky LS. *See* Jones HM
Pine DS. *See* Monk CS
Pipkin SS. *See* Otte C
Pistis M, Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL. Adolescent exposure to cannabinoids induces long-lasting chnages in the response to drugs of abuse of rat midbrain dopamine neurons, 86
Pol HEH. *See* Janssen J; van Haren NEM
Pongrac JL, Middleton FA, Peng L, Lewis DA, Levitt P, Mirnics K. Heat shock protein 12A shows reduced expression in the prefrontal cortex of subjects with schizophrenia, 943
Pope HG Jr. *See* Hudson JI
Potash JB. *See* Schulze TG
Potenza MN. *See* Tucker KA
Powell SB. *See* Harte MK
Power K, DeMartino R. Co-occurring disorders and achieving recovery: the Substance Abuse and Mental Health Services Administration perspective, 721
Praschak-Rieder N, Hussey D, Wilson AA, Carella A, Lee M, Dunn E, Willeit M, Bagby RM, Houle S, Meyer JH. Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: an [^{18}F] MPPF positron emission tomography study, 587
Price LH. *See* Carpenter LL; Tyrka AR
Printz D. *See* Malaspina D
Pryce CR, Dettling AC, Spengler M, Schnell CR, Feldon J. Deprivation of parenting disrupts development of homeostatic and reward systems in marmoset monkey offspring, 72
Purvis R. *See* Jones HM
Putnam KT. *See* Sunderland T

Quiroz JA. *See* Zarate CA Jr

Rabe-Hesketh S. *See* McDonald C; Toulopoulou T
Radomski MW. *See* Chrapko WE
Rajkowska G. *See* Stockmeier CA
Ramnani N, Behrens TEJ, Penny W, Matthews PM. New approaches for exploring anatomical and functional connectivity in the human brain, 613
Rapoport SI. *See* Ghelardoni S
Ratner Y. *See* Korostishevsky M
Rauch SL. *See* Cannistraro PA
Regenold WT. *See* Carpenter LL
Reich T. *See* Schulze TG
Renner JA Jr. How to train residents to identify and treatment of dual diagnosis patients, 810
Renshaw PF. *See* Friedman SD
Reulbach U. *See* Bönsch D
Reynolds GP. *See* Harte MK
Reynolds LM. *See* Harte MK
Ribchester T. *See* van Haren NEM
Rich AS. *See* Argyropoulos SV
Rich NC. *See* Argyropoulos SV
Riddle MA. *See* Vitiello B
Ries RK. *See* Comtois KA

Rilling JK, Winslow JT, Kilts CD. The neural correlates of mate competition in dominant male rhesus macaques, 364
Ritsner M. *See* Korostishevsky M
Rizavi HS. *See* Dwivedi Y
Robbins TW. *See* Hutton SB
Ron MA. *See* Bagary MS
Rothwell JC. *See* Lang N
Rouillard C. *See* Ethier I
Rounsaville BJ. Treatment of cocaine dependence and depression, 803
Roy-Byrne P. *See* Comtois KA
Rubino V. *See* Bertolino A
Rubio MA. *See* Müller R-A
Rush AJ, Trivedi M, Carmody TJ, Biggs MM, Shores-Wilson K, Ibrahim H, Crismon ML. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies, 46
Russ C. *See* D'Souza UM
Russo JE. *See* Comtois KA
Ruwe WD. *See* Tucker P
Ryan ND. *See* Chen BK

Sakamoto K. *See* Kunugi H
Sanacora G. *See* Kugaya A
Sanches M. *See* Chen BK
Sapolsky RM. Is impaired neurogenesis relevant to the affective symptoms of depression, 137
Sassi R. *See* Chen BK
Sassi RB, Brambilla P, Hatch JP, Nicoletti MA, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. Reduced left anterior cingulate volumes in untreated bipolar patients, 467
Scarabino T. *See* Bertolino A
Schaefer TL. *See* Brown RW
Scheftner W. *See* Schulze TG
Scheurich A. *See* Fellgiebel A
Schick M. *See* Kellner M
Schmidt LG. *See* Fellgiebel A
Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, Braus DF, Gattaz WF. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study, 41
Schnack HG. *See* Janssen J
Schnell CR. *See* Pryce CR
Schork NJ. *See* Stein MB
Schulze K. *See* Toulopoulou T
Schulze TG, Buervenich S, Badner JA, Steele CJM, Detera-Wadleigh SD, Dick D, Foroud T, Cox NJ, MacKinnon DF, Potash JB, Berretini WH, Byerley W, Coryell W, DePaulo R Jr, Gershon ES, Kelsoe JR, McInnis MG, Murphy DL, Reich T, Scheftner W, Nurnberger JI Jr, McMahon FJ. Loci on chromosomes 6q and 6p interact to increase susceptibility to bipolar affective disorder in the National Institute of Mental Health Genetics Initiative Pedigrees, 18
Schulzer M. *See* de la Fuente-Fernández R
Schweitzer JB, Lee DO, Hanford RB, Zink CF, Ely TD, Tagamets MA, Hoffman JM, Grafton ST, Kilts CD. Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related to brain activity, 599
Schwieler L. *See* Erhardt S
Seibyl JP. *See* Fujita M; Kugaya A
Sekine Y. *See* Yamada K
Senoo H. *See* Iijima Y
Shaltiel G, Shamir A, Shapiro J, Ding D, Dalton E, Bialer M, Harwood AJ, Belmaker RH, Greenberg ML, Agam G. Valproate decreases inositol biosynthesis, 868
Sham P. *See* McDonald C; van Haren NEM
Shamir A. *See* Shaltiel G
Shapiro J. *See* Shaltiel G
Sharma T. *See* van Haren NEM
Shin LM. *See* Cannistraro PA
Shores-Wilson K. *See* Rush AJ
Shors TJ. *See* Leuner B
Shudo K. *See* Ethier I
Shukla PK. *See* Dwivedi Y
Shumway M. *See* Drake RE
Siebner HR. *See* Lang N
Siessmeier T. *See* Fellgiebel A
Silverstone PH. *See* Willson MC
Singh J. *See* Zarate CA Jr
Smith K. *See* Grillon C
Smyrnis N. *See* Stefanis NC
Snow J. *See* Vythilingam M
Soares H. *See* Sunderland T
Soares JC. *See* Chen BK; Sassi RB
Someya T. *See* Ide M
Sørensen JC. *See* Bjarkam CR
Southwick SM. *See* Fujita M
Spengler M. *See* Pryce CR
Staib LH. *See* Vythilingam M
Staley JK. *See* Kugaya A
Steele CJM. *See* Schulze TG
Stefanis CN. *See* Stefanis NC
Stefanis NC, Van Os J, Avramopoulos D, Smyrnis N, Evdokimidis I, Hantoumi I, Stefanis CN. Variation in catechol-*O*-methyltransferase *val*^{158}*met* genotype associated with schizotypy but not cognition: a population study in 543 young men, 510
Stein MB, Schork NJ, Gelernter J. A polymorphism of the b1-adrenergic receptor is associated with low extraversion,217
Stellitano KE. *See* Wallace TL
Stickgold R. *See* Manoach DS
Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY, Uylings HBM, Friedman L, Rajkowska G. Cellular changes in the postmortem hippocampus in major depression, 640
Stoessl AJ. *See* de la Fuente-Fernández R
Stoll AL. *See* Friedman SD
Stover E. *See* Green MF
Straube T, Kolassa I-T, Glauer M, Mentzel H-J, Miltner WHR. Effect of task conditions on brain responses to threatening faces in social phobics: an event-related functional magnetic resonance imaging study, 921
Strong DR. *See* Tyrka AR
Struttmann T. *See* Kellner M
Sullivan MA. *See* Nunes EV
Sun Y. *See* Huan M
Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM. Cerebrospinal fluid ß-amyloid$_{1-42}$ and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele, 670
Suzuki K. *See* Yamada K
Suzuki T. *See* Ikeda M; Kunugi H
Swartz C. *See* Parvin MM

Swerdlow NR. *See* Harte MK
Symms MR. *See* Bagary MS

Tagamets MA. *See* Schweitzer JB
Tahir E. *See* D'Souza UM
Tajima O. *See* Washizuka S
Takao H. *See* Ide M; Yamada K
Takei N. *See* Yamada K
Tamminga CA. *See* Frost DO
Tatsumi M. *See* Kunugi H
Taylor JR. *See* Chambers RA
Taylor T. *See* Jones HM
Teicher MH, Dumont NL, Ito Y, Vaituzis C, Giedd JN, Andersen SL. Childhood neglect is associated with reduced corpus callosum area, 80
Terasawa K. *See* Huan M
Thacker SK. *See* Brown RW
Tharmalingam S. *See* Levitan RD
Theberge DC. *See* Altshuler LL
Thompson KN. *See* Brown RW
Thron A. *See* Daumann J
Tiemeier H. *See* Padmos RC
Tohyama M. *See* Yamada K
Tomita YA. *See* Ghelardoni S
Torrey EF, Dhavale D, Lawlor JP, Yolken RH. Autism and head circumference in the first year of life, 892
Toulopoulou T, Grech A, Morris RG, Schulze K, McDonald C, Chapple B, Rabe-Hesketh S, Murray RM. The relationship between volumetric brain changes and cognitive function: a family study on schizophrenia, 447
Toyota T. *See* Ide M; Yamada K
Trakalo J. *See* Wong AHC
Tranel D. *See* Buchanan TW
Trautman RP. *See* Tucker P
Trivedi M. *See* Rush AJ
Tucker KA, Potenza MN, Beauvais JE, Browndyke JN, Gottschalk C, Kosten TR. Perfusion abnormalities and decision making in cocaine dependence, 527
Tucker P, Ruwe WD, Masters B, Parker DE, Hossain A, Trautman RP, Wyatt DB. Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder, 121
Tyrka AR, Carpenter LL, McDougle CJ, Kirwin PD, Owens MJ, Nemeroff CB, Strong DR, Price LH. Increased cerebrospinal fluid corticotropin-releasing factor centrations during tryptophan depletion in healthy adults, 531

Umhau JC. *See* Hibbeln JR
Undie AS. *See* Bai J
Uylings HBM. *See* Lindauer RJL; Stockmeier CA

Vaituzis C. *See* Teicher MH
Van Bockstaele EJ. *See* Mannelli P
van Dyck CH. *See* Kugaya A
van Eck-Smit BLF. *See* Lindauer RJL
van Gorp WG. *See* Altshuler LL
van Haren NEM, Picchioni MM, McDonald C, Marshall N, Davis N, Ribchester T, Pol HEH, Sharma T, Sham P, Kahn RS, Murray RM. A controlled study of brain structure in monozygotic twins concordant and discordant for schizophrenia, 454
Van Heertum R. *See* Malaspina D
Van Os J. *See* Stefanis NC
Van Tol HHM. *See* Wong AHC
Vangel MG. *See* Manoach DS
Vass A. *See* Kremer I
Vaughan P. *See* Wignall EL
Ventura J. *See* Altshuler LL
Verhoeff NPLG. *See* Fujita M
Vermetten E. *See* Vythilingam M
Vieta E. *See* Calabrese JR
Vitiello B, Heiligenstein JH, Riddle MA, Greenhill LL, Fegert JM. The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration, 3
Vlieger E-J. *See* Lindauer RJL
Volkow ND. The reality of comorbidity: depression and drug abuse, 714
Vollmayr B. *See* Henn FA
Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, Anderson ER, Snow J, Staib LH, Charney DS, Bremner JD. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment, 101

Wagner E. *See* Luo T
Wallace TL, Stellitano KE, Neve RL, Duman RS. Effects of cyclic adenosine monophosphate response element binding protein overexpression in the basolateral amygdala on behavioral models of depression and anxiety, 151
Wang SJ. *See* Chen Q
Wang X, Dow-Edwards D, Anderson V, Minkoff H, Hurd YL. In utero marijuana exposure associated with abnormal amygdala dopamine D_2 gene expression in the human fetus, 909
Wang XY. *See* Chen Q
Washizuka S, Iwamoto K, Kazuno A-a, Kakiuchi C, Mori K, Kametani M, Yamada K, Kunugi H, Tajima O, Akiyama T, Nanko S, Yoshikawa T, Kato T. Association of mitochondrial complex I subunit gene *NDUFV2* at 18p11 with bipolar disorder in Japanese and the National Institute of Mental Health Pedigrees, 483
Watanabe S. *See* Huan M
Webster MJ. *See* Perlman WR
Wedig MM. *See* Cannistraro PA
Weickert CS. *See* Perlman WR
Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF, Weinberger DR. Catechol-O-methyltransferase *Val*$^{108/158}$*met* genotype predicts working memory response to antipsychotic medications, 677
Weinberger DR. *See* Bertolino A; Green MF; Weickert TW
Whalley H. *See* Harris JM
Whooley MA. *See* Otte C
Wiedemann K. *See* Kellner M
Wignall EL, Dickson JM, Vaughan P, Farrow TFD, Wilkinson ID, Hunter MD, Woodruff PWR. Smaller hippocampal volume in patients with recent-onset posttraumatic stress diso832rder
Wilczek K. *See* Schmitt A
Wilhelm S. *See* Cannistraro PA
Wilkinson ID. *See* Wignall EL
Willeit M. *See* Praschak-Rieder N
Williams MT. *See* Brown RW
Williams SS. *See* Jones HM
Willson MC, Wilman AH, Bell EC, Asghar SJ, Silverstone PH. Dextroamphetamine causes a change in regional brain activity in vivo during cognitive tasks: a functional magnetic

resonance imaging study of blood oxygen level-dependent response, 284
Wilman AH. *See* Willson MC
Wilson AA. *See* Praschak-Rieder N
Winslow JT. *See* Rilling JK
Winterer G. *See* Fellgiebel A
Wisner KL, Hanusa BH, Peindl KS, Perel JM. Prevention of postpartum episodes in women with bipolar disorder, 592
Witchel HJ. *See* Argyropoulos SV
Woldehawariat G. *See* Monk CS
Wolf G. *See* Keilhoff G
Wong AHC, Trakalo J, Likhodi O, Yusuf M, Macedo A, Azevedo M-H, Klempan T, Pato MT, Honer WG, Pato CN, Van Tol HHM, Kennedy JL. Association between schizophrenia and the syntaxin 1A gene, 24
Woodruff PWR. *See* Wignall EL
Wright CI. *See* Cannistraro PA
Wyatt DB. *See* Tucker P

Xie H. *See* Drake RE

Yamada K. *See* Ide M; Kunugi H; Washizuka S
Yamada K, Nakamura K, Minabe Y, Iwayama-Shigeno Y, Takao H, Toyota T, Hattori E, Takei N, Sekine Y, Suzuki K, Iwata Y, Miyoshi K, Honda A, Baba K, Katayama T, Tohyama M, Mori N, Yoshikawa T. Association analysis of *FEZ1* variants with schizophrenia in Japanese cohorts, 683
Yamanouchi Y. *See* Ikeda M
Yang R. *See* Altemus M
Yassouridis A. *See* Kellner M
Yates S. *See* Harris JM
Yolken RH. *See* Torrey EF
Yoshida M. *See* Kunugi H
Yoshikawa T. *See* Ide M; Kunugi H; Washizuka S; Yamada K
Young EA. *See* Cameron OG
Young EA, Abelson JL, Cameron OG. Effect of comorbid anxiety disorders on the hypothalamic-pituitary-adrenal axis response to a social stressor in major depression, 113
Young EA, Breslau N. Saliva cortisol in posttraumatic stress disorder: a community epidemiologic study, 205
Youngstrom EA. *See* Calabrese JR
Yusuf M. *See* Wong AHC

Zalcman S. *See* Green MF
Zanelli J. *See* McDonald C
Zarahn E. *See* Monk CS
Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study, 54
Zhu SM. *See* Chen Q
Zill P, Büttner A, Eisenmenger W, Möller H-J, Bondy B, Ackenheil M. Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims, 581
Zink CF. *See* Schweitzer JB
Zoghbi SS. *See* Fujita M

SUBJECT INDEX TO VOLUME 56

Adolescents
  amygdala development in, with bipolar disorder, 399
  cannabinoid use by, 86
  substance abuse in, 764
Affective spectrum disorders
  family studies of, 884
-1438A/G single nucleotide polymorphism
  of 5-hydroxytryptamine type 2A receptor gene, 406
AKT1
  schizophrenia and, 698
Alcohol abuse
  depression and, antidepressant treatment for, 785
  mood disorders and, 718
Alcohol craving
  alpha synuclein mRNA levels and, 984
Alpha synuclein
  alcohol craving and, 984
Alzheimer disease
  APOE ϵ4 allele in, 670
  cerebrospinal fluid β-amyloid$_{1-42}$ and tau in, 670
  in mild cognitive impairment, 279
  phospho-tau levels in, 279
Amitriptyline
  antidepressant effects of, 657
  hippocampal cell proliferation affected by, 657
Amygdala
  development of, in adolescents and young adults with bipolar disorder, 399
  estrogen receptor alpha messenger ribonucleic acid in, 844
  glucocorticoid levels in, 844
  in obsessive-compulsive disorder patients, 916
  responses to emotional faces, in obsessive-compulsive disorder, 916
Animal models. *See also* Rats
  learned helplessness, 30
  neurogenesis, 317
  sexual jealousy in males, 364
Anterior cingulate, left
  in bipolar disorder, 467
Antidepressants
  alcohol abuse and depression comorbidity treated with, 785
  cyclic adenosine monophosphate response element binding protein levels in amygdala affected by, 151
  female response to, 964
  ketogenic diet as form of, 981
  male response to, 964
  neurogenesis effects on, 137
  nicotinic acetylcholine receptor antagonism and, 657
  pramipexole, 54
Antipsychotics
  atypical, 441
  working memory response to, catechol-*O*-methyltransferase *val*$^{108/158}$*met* genotype as predictor of, 677
Antisaccades
  in schizophrenia, 553, 620
Anxiety disorders
  attention to threat in, 607
  behavioral models of, 151
  conditioned taste aversion and, 901
  depression comorbidity with, effect on central nervous system noradrenergic function, 875
  family studies of, 884
  hypothalamic-pituitary-adrenal axis response affected by, 113
  major depressive disorder and, 113
  prepubertal children with, 198
APOE ϵ4 allele, 670
Arachidonic acid
  phospholipase A_2-mediated release of, carbamazepine effects on, 248
Attention to threat, 607
Attention-deficit/hyperactivity disorder
  executive functioning in, methylphenidate effects on, 597
  ocular motor behavior in, inhibitory deficits in, 333
  prefrontal cortex–basal ganglia circuitry abnormalities in, 333
Atypical antipsychotics, 441
Autism
  cerebellar function in, 269
  head circumference and, 892
  sequence learning in, premotor cortex activity patterns during, 323
Autoimmunity, organ-specific
  in bipolar disorder, 476

β$_1$-adrenergic receptor polymorphisms, 217
β-amyloid$_{1-42}$, cerebrospinal fluid
  in Alzheimer's disease, 671
Basal ganglia
  attention-deficit/hyperactivity disorder-related abnormalities, 333
Behavior
  amitriptyline effects on, 657
  suicidal, 757
Behavioral strategies
  substance abuse and mood disorder comorbidity treated with, 778
Benzodiazepine receptors, central type
  in Gulf War veterans with posttraumatic stress disorder, 95
Binge eating
  dopamine-4 receptor gene and, 665
  seasonal affective disorder and, 665
Bipolar disorder
  in adolescents, 399
  amygdala development in adolescents and young adults with, 399
  brain morphometry studies in, 411
  carbamazepine for, 248
  chromosome 6p and, 18
  chromosome 6q and, 18
  genetics of, 18
  glutamate in, 340
  glutamic acid decarboxylase-65 in, 476
  glutamic acid decarboxylase-67 in, 476
  H/K adenosine triphosphatase in, 476
  left anterior cingulate volumes in, 467
  lithium for, 340
  magnetic resonance imaging studies in, 411
  mood stabilizers for, 957
  NDUFV2 at 18p11 in, 483
  neurocognitive function in, 560
  organ-specific autoimmunity in, 476
  postpartum episodes in women with, 592
  pramipexole for, 54

0006-3223/04/$30.00
doi:10.1016/S0006-3223(04)01196-5

BIOL PSYCHIATRY 2004;56:1004–1011

© 2004 Society of Biological Psychiatry

relapse of, 957
substance abuse and
description of, 738
medications for, 771
outcomes of, 749
suicidal behavior risks, 757
thyroperoxidase antibodies in, 476
Val66Met polymorphism of brain-derived neurotrophic factor gene and, 376
valproic acid for, 340
voxel-based morphometry in, 544
in young adults, 399
Blood oxygen level-dependent response
functional magnetic resonance imaging study of, 284
Brain. *See also* Amygdala; Cerebellum; Hippocampus
anatomical connectivity in, 613
connectivity in, 613
diffusion tensor imaging of, 613
environmental influences on, 454
functional connectivity in, 613
genetic influences on, 454
magnetic resonance imaging morphometry studies of, in bipolar disorder, 411
regional activity, dextroamphetamine effects on, 284
retinoic acid effects on, 971
vitamin A effects on maturation of, 971
volume of
cognitive function and, in schizophrenia, 447
in monozygotic twins with schizophrenia, 454
Brain-derived neurotrophic factor gene
Val66Met polymorphism of, 376

Calcyon, 427
Cancer
psychotherapy effects on survival from, 61
Cannabinoids
adolescent exposure, dopaminergic neurons affected by, 86
Carbamazepine
cytosolic phospholipase A_2 expression downregulated by, 248
Carbon dioxide inhalation
panic disorder studies using, 862
Catechol-*O*-methyltransferase *val*^{158}*met* genotype
cognition and, 510
schizophrenia and, 510
working memory response to antipsychotic medications predicted by, 677
Central nervous system noradrenergic function
anxiety disorder and depression comorbidity effects on, 875
Central type benzodiazepine receptors
in Gulf War veterans with posttraumatic stress disorder, 95
Cerebellum
in autism, 269
functional magnetic resonance imaging of, 269
Cerebral blood flow
in posttraumatic stress disorder, 853
regional, in schizophrenia, 931
Cerebral perfusion
cocaine dependence and, 527
Cerebrospinal fluid
β-amyloid$_{1-42}$, in Alzheimer's disease, 671
corticotropin-releasing factor concentrations, during tryptophan depletion, 531
monoamine metabolites in, 418
neurochemistry changes of, in pregnancy, 386
tau, in Alzheimer's disease, 671
vagus nerve stimulation effects on monoamine metabolites in, 418
Childhood neglect
corpus callosum affected by, 80
Children
autism in, 892
depression in
prepubertal children, 198
serotonin transporter-linked promoter polymorphism in, 292
mothers' neural activation in response to pictures of, 225
prepubertal
with anxiety disorders, 198
with depressive disorders, 198
twenty-four-hour cortisol secretion patterns in, 198
research regarding
publicly and industry-funded, 3
Chromogranin B gene
schizophrenia and, 10
Chromosome 6p
bipolar disorder and, 18
Chromosome 6q
bipolar disorder and, 18
Cocaine dependence
cerebral perfusion abnormalities and, 527
decision-making ability and, 527
depression associated with, 803
rat studies of, 308
ventral hippocampus and, 308
Cognition
catechol-*O*-methyltransferase *val*^{158}*met* genotype and, 510
Cognitive function
in schizophrenia, 301, 447
volumetric brain changes and, 447
Conditioned taste aversion
anxiety-like state and, 901
Coronary heart disease
depression in patients with, 241
twenty-four-hour urinary cortisol in, 241
Corpus callosum
childhood neglect effects on, 80
Corticosterone
quinpirole effects on, 161
Corticotrophin-releasing hormone
in domestic violence perpetrators, 895
Corticotropin-releasing factor
cerebrospinal fluid, during tryptophan depletion, 531
Cortisol
circadian regulation of, 651
hippocampus damage effects on secretion of, 651
intimate partner violence effects on, 233
in major depressive disorder, 101
saliva, in posttraumatic stress disorder, 205
selective serotonin reuptake inhibitor effects on, 121
twenty-four-hour secretion
in coronary heart disease patients, 241
in prepubertal children, 198
Cushing's syndrome, 837

Cyclic adenosine monophosphate response element binding protein
antidepressant medication effects on, in amygdala, 151
Cytokines, 819

Decision-making ability
cocaine dependence effects on, 527
Dehydroepiandrosterone
intimate partner violence effects on, 233
Depression
affective symptoms in, 137
alcohol dependence and, antidepressant treatment for, 785
anxiety disorder comorbidity with, effect on central nervous system noradrenergic function, 875
behavioral models of, 151
cerebrospinal fluid monoamine metabolites in, 418
in children
prepubertal, 198
serotonin transporter-linked promoter polymorphism in, 292
cocaine dependence and, 803
in coronary heart disease patients, 241
drug abuse comorbidity with, 714
early-onset
hippocampal volume changes in, 825
white matter lesions in, 825
gamma-aminobutyric acid levels in, 418
neurogenesis in, 137, 146
neurons in, 140
norepinephrine and selective serotonin reuptake inhibitors for, 535
norepinephrine levels in, 418
in opiate-dependent patients, 793
outcomes in, 46
prepubertal children with, 198
public sector outpatient studies of, 46
remission of, 46
selective serotonin reuptake inhibitors. *see* Selective serotonin reuptake inhibitors
tryptophan depletion effects on selective serotonin reuptake inhibitor treatment of, 587
twenty-four-hour urinary cortisol levels and, in coronary heart disease patients, 241
vagus nerve stimulation for, 418
white matter lesions in, 825
Dextroamphetamine
regional brain activity affected by, 284
Diet
ketogenic, 981
low-carbohydrate, 981
Diffusion tensor imaging, 613
Divalproex, for postpartum episodes in bipolar disorder patients, 592
Docosahexaenoic acid
domestic violence perpetrators' level of, 895
haloperidol-induced dyskinesias in mice reduced by, 522
suicide attempts and, 490
Domestic violence perpetrators. *See also* Intimate partner violence
corticotrophin-releasing hormone levels in, 895
omega-3 fatty acid levels in, 895
Dopamine
schizophrenia-related abnormalities in, 427
Dopamine D_2 gene
in utero marijuana exposure effects on expression of, in fetus, 909
Dopamine-4 receptor gene
binge eating and, 665
tandem duplication polymorphism in 5' flanking region of, 691
weight gain and, 665
Dopamine receptor-interacting proteins, 427
Dopaminergic neurons
cannabinoids' effect on, 86
Drug abuse. *See* Substance abuse
Dual diagnosis. *See also* Substance abuse
epidemiology of, 730
patient's perspective of, 726, 728
resident training in how to treat, 810
treatment of, 810
Dyskinesia, haloperidol-induced
docosahexaenoic acid effects on, 522
Nur77 and, 522
retinoid receptors and, 522

Early-onset depression
hippocampal volume changes in, 825
white matter lesions in, 825
Ectasy
cortical function patterns in users of, 349
working memory performance in users of, 349
Eicosapentaenoic acid, 490
Electroconvulsive therapy, 905
Estrogen receptor alpha messenger ribonucleic acid
in amygdala of mentally ill patients, 844
Executive dysfunction
in schizophrenia, 553
Executive functioning
in attention-deficit/hyperactivity disorder, methylphenidate effects on, 597
Extraversion
b1-adrenergic receptor polymorphism associated with, 217
^{18}F MPPF positron emission tomography, 587

Face processing, 225
Faces
amygdala responses to, in obsessive-compulsive disorder, 916
brain responses to threatening faces, in social phobics, 921
Family studies
of affective spectrum disorders, 884
of fibromyalgia, 884
FDZ3, 462
Fetus
marijuana exposure in utero, 909
FEZ1
schizophrenia and, 683
^{18}F-fluoro-2-deoxy-D-glucose positron emission tomography
mild cognitive impairment evaluations, 279
Fibromyalgia
family study of, 884
First-episode schizophrenia
antisaccades in, 553, 620
executive dysfunction in, 553
first-episode, 553
oculomotor function in, 620

quetiapine for, 938
smooth pursuit in, 553, 620
Fluoxetine
female response to, 964
hippocampal cell proliferation affected by, 570
male response to, 964
prefrontal cortex cell proliferation affected by, 570
Functional magnetic resonance imaging
blood oxygen level-dependent response studies, 284
brain responses to threatening faces in social phobics, 921
cerebellar function in autism studied using, 269
quetiapine treatment for schizophrenia evaluated using, 938
working memory performance in ectasy users evaluated using, 349

Gamma-aminobutyric acid
pregnancy-related changes, 386
vagus nerve stimulation effects on, in depressed patients, 418
Gene functioning studies
genetically manipulated mice used in, 381
Genetically manipulated mice, 381
G72/G30 locus
schizophrenia and, 169
Glucocorticoids
in amygdala of mentally ill patients, 844
Glutamate
in bipolar disorder, 340
lithium effects on, 340
Glutamic acid decarboxylase-65, 476
Glutamic acid decarboxylase-67, 476
Gulf War veterans
central type benzodiazepine receptors in, 95
with posttraumatic stress disorder, 95
Gyrification index
in schizophrenia, 182

Haloperidol-induced dyskinesias
docosahexaenoic acid effects on, 522
Nur77 and, 522
retinoid receptors and, 522
Head circumference
autism and, 892
Hippocampus
cells
amitriptyline effects on, 657
major depression-related changes in, 640
in Cushing's syndrome, 837
damage to, cortisol secretion affected by, 651
fluoxetine effects on cell proliferation in, 570
olanzapine effects on cell proliferation in, 570
Pavlovian conditioning in endogenous hypercortisolism, 837
pyramidal neurons in, 640
ventral, cocaine sensitization in, 308
volume of
in early-onset depression, 825
in major depressive disorder, 101, 640
in posttraumatic stress disorder, 356, 832
in schizophrenia, 317
H/K adenosine triphosphatase, 476
Homeostatic systems
parenting deprivation effects on, 72
5-Hydroxytryptamine type 2A receptor gene
-1438A/G single nucleotide polymorphism in, 406
Hypercortisolism, 837
Hypothalamic-pituitary-adrenal axis response
in major depressive disorder, 113
stress-induced activation of, 205

Industry-funded research
in children, 3
Inositol
valproate effects on biosynthesis of, 868
Interferon-α, 819
Intimate partner violence. *See also* Domestic violence perpetrators
cortisol changes secondary to, 233
dehydroepiandrosterone changes secondary to, 233

Ketamine model of schizophrenia, 317
Ketogenic diet, 981
Kynurenic acid
schizophrenia and, 255

Lamotrigine
schizophrenia treated with, 441
Learned helplessness
animal models of, 30
cyclic adenosine monophosphate response element binding protein levels and, 151
protein kinase A alterations associated with, 30
stress-induced, 30
Learning
sequence
in autistic patients, 323
premotor cortex activity patterns during, 323
sleep-dependent procedural, in schizophrenia, 951
Left anterior cingulate volume
in bipolar disorder, 467
Lithium
bipolar disorder treated with, 340
brain chemistry affected by, 340
glutamate levels affected by, 340
Low-carbohydrate diets, 981

Magnetic resonance imaging
of brain morphometry in bipolar disorder, 411
functional
blood oxygen level-dependent response studies, 284
brain responses to threatening faces in social phobics, 921
cerebellar function in autism studied using, 269
quetiapine treatment for schizophrenia evaluated using, 938
working memory performance in ectasy users evaluated using, 349
Major depressive disorder. *See also* Depression
anxiety disorders and, 113
cortisol in, 101
hippocampal volume in, 101, 640
hypothalamic-pituitary-adrenal axis response in, 113
memory in, 101
nitric oxide metabolites in, 129
nitric oxide synthase activity in, 129
Male sexual jealousy, 364
Marijuana
in utero exposure to, 909

Mate competition, 364
MDMA. *see* Ectasy
Medial frontal gyrus
  in posttraumatic stress disorder, 853
Memory
  in major depressive disorder, 101
  working
    catechol-*O*-methyltransferase *val*$^{108/158}$*met* genotype as predictor of response to, to antipsychotics, 677
    in ectasy users, 349
    functional magnetic resonance imaging of, 349
Mental disorders
  anxiety. *See* Anxiety disorders
  depression. *See* Depression; Major depressive disorder
  schizophrenia. *See* Schizophrenia
  substance abuse comorbidity with. *See also* Dual diagnosis
    dual diagnosis of, 726, 728, 730
    epidemiology of, 730
    health care for, 703
    patient's perspective on, 726
    recovery for, 721
    research opportunities, 723
    Substance Abuse and Mental Health Services Administration perspective of, 721
3,4-Methylenedioxymethamphetamine. *see* Ectasy
Methylphenidate
  executive functioning in attention-deficit/hyperactivity disorder affected by, 597
Metyrapone tests
  in panic disorder patients, 898
Mice
  genetically manipulated, 381
  haloperidol-induced dyskinesias in, 522
  retinoic-acid critical period in postnatal brain of, 971
Mild cognitive impairment
  Alzheimer disease in, 279
  phospho-tau levels and ^{18}F-fluoro-2-deoxy-D-glucose positron emission tomography findings in, 279
Mitochondrial complex I subunit gene, 483
Mood disorders
  alcohol use disorders and, 718
  anxiety. *See* Anxiety
  depression. *See* Depression; Major depressive disorder
  substance abuse and
    behavioral strategies for, 778
    description of, 718

N-3 fatty acids
  in domestic violence perpetrators, 895
  suicide attempts and, 490
N-Acetylaspartate
  in temporal cortex of rats reared in isolation, 296
Naltrexone
  opioid withdrawal reduction using, 261
NDUFV2, 483
Neglect, childhood
  corpus callosum affected by, 80
Neurocognitive function
  in bipolar disorder, 560
  in schizophrenia, 560
Neurodegenerative disorders
  Parkinson's disease. *see* Parkinson's disease
  therapeutic strategies for, 213

Neurogenesis
  animal model of, 317
  in depression, 137, 146
  schizophrenia and, 317
Neuron(s)
  in depression, 140
  dopaminergic, cannabinoids' effect on, 86
Neuronal calcium sensor-1, 427
Neuroplasticity
  schizophrenia and, 540, 629
Neurotrophic factors
  quinpirole effects on, 161
Nicotinic acetylcholine receptors, high-affinity, 657
Nitric oxide metabolites
  in major depressive disorder, 129
Nitric oxide synthase
  in major depressive disorder, 129
Noradrenergic function
  anxiety disorder and depression comorbidity effects on, 875
Norepinephrine
  vagus nerve stimulation effects on, in depressed patients, 418
Nur77, 522

Obsessive-compulsive disorder
  amygdala responses to human faces in patients with, 916
Olanzapine
  hippocampal cell proliferation affected by, 570
  prefrontal cortex cell proliferation affected by, 570
  schizophrenia treated with, 190
Omega-3 fatty acids
  in domestic violence perpetrators, 895
  suicide attempts and, 490
Opiate dependence
  depression in patients with, 793
Opioid withdrawal
  naltrexone administration effects on, 261
Organ-specific autoimmunity
  in bipolar disorder, 476

Panic disorder
  carbon dioxide inhalation and, emotional and physiological response to, 862
  metyrapone tests in patients with, 898
  respiratory irregularity in, 393
  smoking and, 393
Parenting deprivation
  description of, 72
  homeostatic systems affected by, 72
  reward systems affected by, 72
Parkinson's disease
  dopamine in, 67
  placebo effect in, 67
  reward circuitry in, 67
  therapeutic strategies for, 213
Phospholipase A_2
  arachidonic acid release mediated by, 248
  carbamazepine effects on expression of, 248
Phospholipids
  thalamic membrane, in schizophrenia, 41
Phospho-tau levels
  in Alzheimer disease, 279

Placebo effect
dopamine effects on, 67
in Parkinson's disease, 67
Positron emission tomography
^{18}F MPPF, 587
^{18}F-fluoro-2-deoxy-D-glucose, 279
Postpartum episodes
in bipolar disorder patients, 592
divalproex for, 592
Posttraumatic stress disorder
cerebral blood flow studies, 853
Gulf War veterans with, central type benzodiazepine receptors in, 95
hippocampal volume in, 356, 832
medial frontal gyrus dysfunction in, 853
in police officers, 853
saliva cortisol levels in, 205
script-driven imagery studies, 853
selective serotonin reuptake inhibitors for
cortisol changes associated with, 121
neuroimmune changes associated with, 121
Pramipexole
bipolar disorder treated with, 54
Preconditioning
transcranial direct current stimulation, 634
Prefrontal cortex
attention-deficit/hyperactivity disorder-related abnormalities, 333
fluoxetine effects on cell proliferation in, 570
heat shock protein 12A expression in, in schizophrenia, 943
olanzapine effects on cell proliferation in, 570
Pregnancy
cerebrospinal fluid neurochemistry changes in, 386
gamma-aminobutyric acid alterations during, 386
Premotor cortex
abnormal activity patterns in, during sequence learning in autistic patients, 323
stimulation of, in schizophrenia, 628
Prepulse inhibition
kynurenic acid effects on, 255
Prolactin
cerebrospinal fluid, during pregnancy, 386
Protein kinase A
learned helplessness and, 30
Psychopathy personality inventory, 516
Psychopharmacology research
in children, 3
publicly and industry-funded, 3
Psychotherapy
cancer survival affected by, 61
Publicly funded research
in children, 3
Pyramidal neurons, 640

Quetiapine
first-episode schizophrenia treated with, 938
Quinpirole
corticosterone and, 161
Morris water task performance in early postweaning rats impaired by, 161
neonatal treatment, 161
neurotrophic factors affected by, 161

Rats. *See also* Animal models
anxiety studies in, 151
cocaine abuse studies, 308
cyclooxygenase activity in, 248
depression studies in, 151
isolation rearing of, *N*-acetylaspartate reduction in temporal cortex secondary to, 296
learned helplessness models, 30
olanzapine and fluoxetine effects on cell proliferation in hippocampus and prefrontal cortex, 570
opioid withdrawal reduction using naltrexone in, 261
Regional brain activity
dextroamphetamine effects on, during cognitive tasks, 284
Regional cerebral blood flow
in schizophrenia, 931
Repetitive transcranial magnetic stimulation
rapid-rate, motor cortex sensitization to, 634
schizophrenia evaluations using, 628
Research
in children, 3
publicly and industry-funded, 3
Retinoic acid, 971
Retinoid receptors, 522
Reward systems
parenting deprivation effects on, 72

Saliva cortisol, in posttraumatic stress disorder, 205
Schizophrenia
AKT1 and, 698
antisaccades in, 553, 620
brain volume in
cognitive function affected by, 447
in monozygotic twins with schizophrenia, 454
calcyon upregulation in, 427
catechol-*O*-methyltransferase *val*^{158}*met* genotype and, 510
chromogranin B gene and, 10
cognitive battery for clinical trials in, 301
cognitive function in, 301, 447
cortical folding in, 182
dopamine system abnormalities in, 427
dual diagnosis, 308
executive dysfunction in, 553
FDZ3 in, 462
FEZ1 and, 683
first-episode, 553, 620
G72/G30 locus associated with, 169
glutamatergic theory of, 169
gyrification index in, 182
heat shock protein 12A expression in prefrontal cortex of patients with, 943
high-risk individuals, 182
hippocampal volume in, 317
ketamine model of, 317
kynurenic acid and, 255
lamotrigine for, 441
monozygotic twins with, 454
neural networks in, 620
neurocognitive function in, 560
neurogenesis and, 317
neuronal calcium sensor-1 upregulation in, 427
neuroplasticity and, 540, 629
olanzapine for, 190
phospholipids in, 41

plasticity and, 629
prefrontal cortex of patients with, 943
premotor cortex stimulation in, abnormal plastic response to, 628
quetiapine for, 938
regional cerebral blood flow patterns in, 931
repetitive transcranial magnetic stimulation in, 628
resting neural activity for distinguishing subgroups of, 931
sensorimotor cortex in, functional lateralization of, 190
single nucleotide polymorphisms and, 177
sleep-dependent procedural learning failure in, 951
smooth pursuit in, 553, 620
subgroups of, 931
synapsin II and, 177
syntaxin 1A gene and, 24
thalamic membrane phospholipids in, 41
voxel-based morphometry in, 544
Seasonal affective disorder, 665
Selective serotonin reuptake inhibitors
norepinephrine and, for depression, 535
posttraumatic stress disorder treated with
cortisol changes associated with, 121
neuroimmune changes associated with, 121
serotonin transporter availability effects on response to, 497
tryptophan depletion reversal of, in social anxiety disorder, 503
Sensorimotor cortex
in schizophrenia, 190
Sequence learning
in autistic patients, 323
premotor cortex activity patterns during, 323
Serotonin
corticotropin-releasing factor and, 531
tryptophan depletion and, 587
Serotonin transporter
selective serotonin reuptake inhibitors treatment response affected by, 497
Serotonin transporter-linked promoter polymorphism
in pediatric-onset depressive disorders, 292
Sexual jealousy in males, 364
Single nucleotide polymorphisms
-1438A/G, 406
FDZ3, 462
schizophrenia and, 177
tryptophan hydroxylase isoform gene, 581
Sleep-dependent procedural learning
in schizophrenia, 951
Smoking
panic disorder and, 393
Smooth pursuit
in schizophrenia, 553, 620
Social anxiety disorder
tryptophan depletion effects on selective serotonin reuptake inhibitors for, 503
Social phobia
brain responses to threatening faces in patients with, 921
Stress
female response to, 964
hypothalamic-pituitary-adrenal axis response induced by, 205
learned helplessness induced by, 30
male response to, 964
Substance abuse
in adolescents, 764
alcohol. *See* Alcohol abuse
bipolar disorder and. *See also* Dual diagnosis
description of, 738
medications for, 771
outcomes of, 749
suicidal behavior risks, 757
cocaine. *See* Cocaine dependence
depression comorbidity with, 714
mental disorders and, comorbidity of. *See also* Dual diagnosis
dual diagnosis of, 726, 728, 730
epidemiology of, 730
health care for, 703
patient's perspective on, 726
recovery for, 721
research opportunities, 723
Substance Abuse and Mental Health Services Administration perspective of, 721
mood disorders and. *See also* Dual diagnosis
behavioral strategies for, 778
description of, 718
treatment of, 764
Substance Abuse and Mental Health Services Administration, 721
Suicide
bipolar disorder and substance abuse as risk factors for, 757
tryptophan hydroxylase isoform gene polymorphism and, 581
Suicide attempts
fish intake and, 490
n-3 fatty acid levels and, 490
Synapsin II
schizophrenia and, 177
Syntaxin 1A gene
schizophrenia and, 24

Tandem duplication polymorphism, in dopamine-4 receptor gene, 691
Taste aversion, conditioned
anxiety-like state and, 901
Tau
cerebrospinal fluid, in Alzheimer's disease, 671
phospho-, in Alzheimer disease, 279
Temporal cortex
N-acetylaspartate reductions in, in rats reared in isolation, 296
Thalamic membrane phospholipids
schizophrenia and, 41
Threat
attention to, 607
Thyroperoxidase antibodies
in bipolar disorder, 476
Transcranial direct current stimulation
motor cortex sensitization to repetitive transcranial magnetic stimulation by, 634
preconditioning using, 634
Tryptophan depletion
cerebrospinal fluid corticotropin-releasing factor concentrations during, 531
selective serotonin reuptake inhibitor therapeutic response reversed by
in depression, 587
in social anxiety disorder, 503

Tryptophan hydroxylase isoform gene
suicide and, 581
Twenty-four-hour cortisol
in coronary heart disease patients, 241
secretion patterns, in prepubertal children, 198

Vagus nerve stimulation
depression treated with, 418
Val66Met polymorphism
of brain-derived neurotrophic factor gene, in bipolar disorder, 376
Valproate
inositol biosynthesis decreased by, 868
substance abuse and bipolar disorder comorbidity treated with, 771
Valproic acid
bipolar disorder treated with, 340
inositol biosynthesis decreased by, 868
Ventral hippocampus
cocaine sensitization in, 308
Vitamin A, 971
Voxel-based morphometry
in bipolar disorder, 544
in schizophrenia, 544

Weight gain
dopamine-4 receptor gene and, 665
White matter lesions
in early-onset depression, 825
Women
intimate partner violence in, 233
seasonal affective disorder in, 665
Working memory
catechol-*O*-methyltransferase $val^{108/158}met$ genotype as predictor of response to, to antipsychotics, 677
in ectasy users, 349
functional magnetic resonance imaging of, 349

Young adults
amygdala development in, with bipolar disorder, 399